2021-11-16-世界卫生组织-Cervical_cancer_Jamaica_2021_country_profile_1页_65kb

Cervical Cancer Summary

Core Statistics

Primary Prevention

• HPV Vaccination Programme:

  • HPV is included in the national vaccination programme.
  • The programme is national in scale and was introduced in 2017.
  • The primary target cohort is girls aged 11-12 years.
  • In 2020, fewer than 1 in 10 girls turning 15 years old received their final HPV vaccination dose.

• Risk Factors:

  • Tobacco use prevalence among women aged 15+ years (2020): 4%
  • Condom use at last high-risk sex: Not Determined (ND)
  • HIV incidence per 1,000 women aged 15+ years (2020): 0.61

Secondary Prevention

• National Screening Programme:

  • Exists (2021)
  • Primary screening test used: Cytology
  • Target age range: 20-64 years
  • Referral system from primary care to secondary and tertiary care: Clearly defined (2021)
  • Programme/guidelines for early detection at primary health care level: Not available (2021)

• Screening Coverage:

  • In 2019, 7 in 10 women had been screened for cervical cancer in the last 5 years.

Treatment and Supportive Care

• National Guidelines on Cervical Cancer Management:

  • Exist (2021)

• Treatment Infrastructure:

  • Cancer centres or departments at tertiary level: Yes
  • Pathology services (laboratories): Yes
  • Cancer surgery: Yes
  • Chemotherapy: Yes
  • Radiotherapy: Yes
  • Brachytherapy units per 10,000 cancer patients (2020): 3
  • Radiotherapy units per 10,000 cancer patients (2020): 7

• Medical Staff (per 10,000 cancer patients):

  • Radiation oncologists (2019): 5
  • Medical physicists (2019): Not Determined (ND)
  • Surgeons (2014): 249
  • Radiologists (2019): 82
  • Nuclear medicine physicians (2019): 7

• Palliative Care:

  • Not generally available in primary health care facilities.
  • Not generally available in community or home-based care.
  • Oral morphine equivalence per capita (2017): 4mg

WHO Cervical Cancer Elimination Strategy Targets for 2030

• 90% of girls should be fully vaccinated with the HPV vaccine by the age of 15.
• 70% of women should be screened with a high-performance test by 35 years of age and again by 45 years of age.
• 90% of women identified with cervical disease should receive treatment.